Diligence memo · auto-generated · as of July 2, 2026
Epiomed Therapeutics, Inc.
Epiomed Therapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Epiomed Therapeutics, Inc. operates in Pharmaceuticals, based in IRVINE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Epiomed Therapeutics, Inc. has raised $2.2M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.2M on 2011-05-31.
Most recent recorded round closed around 2011-05-31.
Valuation (modeled)modeled
Provath models Epiomed Therapeutics, Inc. at approximately $86M (range $1.7M–$672M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.43× the median modeled value of Seed Pharmaceuticals companies in 2010–2012 (58 peers) — value vs value, same stage and era. Within the normal band (143% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 15.1 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 29% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 52% of those peers.
Closest niche peers: First China Pharmaceutical Group, Inc., MediQuest Holdings LLC, Ampla Pharmaceuticals Inc, Biomimetix Pharmaceutical, Inc., Prexa Pharmaceuticals Inc.
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.